ReviewFuture science OA2025
A systematic review of inflammatory bowel disease in Kazakhstan: prevalence, risk factors, and genetic insights.
Review in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory bowel disease is a chronic condition characterized by immune mediated inflammation and primarily includes Crohn's disease and ulcerative colitis.
objectiveThere is an increase rate of incidence of the disease in Kazakhstan. Therefore, it is important to determine the prevalence of the condition in to improve diagnosis and the treatment for the local population.
methodThey current manuscript is a systematic review of the literature that focuses on IBD from Kazakhstan with a focus on prevalence, risk factors including genetic predisposition, disease mechanism, diagnosis and treatment.
resultsThe prevalence of IBD is higher in urban regions, and more prevalent in individuals under the age of 40 years. Genetic studies reported that familial IBD is quite rare in Kazakhstan, suggesting an environmental cause rather than a genetic reason that is driving the increase of prevalence.
conclusionThere are IBD-associated variants linked to immune function and inflammation pathways that may serve as noninvasive biomarkers for disease diagnosis and severity. However, the mechanisms of disease development and drug response may differ across different populations, therefore, there might be a need implement genetic testing to improve therapy and disease management in Kazakhstan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.